Representative Matt Gaetz (R-FL) has introduced an amendment to the appropriations bill that, if passed, would not allow the Department of Justice to use funds from the bill to prevent or delay the approval of an application to research medical marijuana. This past year, the DEA moved to create a new procedure to license more facilities to cultivate marijuana for research after hearing concerns about the lack of quality cannabis for trials. However, since this implementation, the DEA has not acted on any of the applications that have been submitted since the creation of this program in an attempt to keep the already outrageous restrictions.
“Because of marijuana’s draconian schedule 1 status, scientists are hindered in researching its medical potential — and then, because medical research is scarce, its schedule 1 status is upheld. It’s time to break this vicious cycle, and make it easier for researchers to investigate the potential medical uses of cannabis” said Rep. Gaetz. “How many lives throughout the nation could be improved with increased marijuana research — from cancer patients to veterans with PTSD? We do a disservice to them, and to all Americans, by limiting research. The time for change is now.”
Because marijuana is listed as a schedule I drug under the Controlled Substances Act, the federal government does not see it as having any medicinal benefits. Trying to get the DEA to actually act upon these new applications to expand research is extremely difficult and it will be just as difficult to get the DEA accept them. If Gaetz’s proposed amendment is passed, it will make it harder for the DEA to deny these research applications.
In a bipartisan letter, Representatives Gaetz, Rohrabacher (R-CA), Polis (D-CO), and Blumenauer (D-OR) ask Attorney General Jeff Sessions to stop standing in the way of increasing research into marijuana’s medical potential. In the letter, the Representatives write “It is worrisome to think that the Department of Justice, the cornerstone of American civil society, would limit new and potentially groundbreaking research simply because it does not want to follow a rule.”
